Federated learning with multi‐cohort real‐world data for predicting the progression from mild cognitive impairment to Alzheimer's disease
Alzheimer s & Dementia,
Год журнала:
2025,
Номер
21(4)
Опубликована: Апрель 1, 2025
Leveraging
routinely
collected
electronic
health
records
(EHRs)
from
multiple
health-care
institutions,
this
approach
aims
to
assess
the
feasibility
of
using
federated
learning
(FL)
predict
progression
mild
cognitive
impairment
(MCI)
Alzheimer's
disease
(AD).
We
analyzed
EHR
data
OneFlorida+
consortium,
simulating
six
sites,
and
used
a
long
short-term
memory
(LSTM)
model
with
averaging
(FedAvg)
algorithm.
A
personalized
FL
was
address
between-site
heterogeneity.
Model
performance
assessed
area
under
receiver
operating
characteristic
curve
(AUC)
feature
importance
techniques.
Of
44,899
MCI
patients,
6391
progressed
AD.
models
achieved
6%
improvement
in
AUC
compared
local
models.
Key
predictive
features
included
body
mass
index,
vitamin
B12,
blood
pressure,
others.
showed
promise
predicting
AD
by
integrating
heterogeneous
across
institutions
while
preserving
privacy.
Despite
limitations,
it
offers
potential
for
future
clinical
applications.
applied
record
institutions.
improved
prediction
performance,
increase
identified
key
features,
such
as
pressure.
shows
effectiveness
handling
heterogeneity
sites
ensuring
Personalized
pooled
generally
performed
better
than
global
Язык: Английский
Myelopathic motor symptoms overlaying Parkinson’s disease
Practical Neurology,
Год журнала:
2025,
Номер
unknown, С. pn - 004546
Опубликована: Март 26, 2025
Parkinson’s
disease
(PD)
may
increase
the
risk
of
degenerative
cervical
myelopathy,
causing
overlaying
myelopathic
motor
symptoms
that
can
be
challenging
to
identify.
However,
this
diagnosis
must
not
missed,
given
profound
and
lasting
disability
benefit
surgical
intervention.
We
describe
a
fortnight
in
which
three
patients
with
PD
were
admitted
our
inpatient
movement
disorders
service
myelopathy;
each
highlighting
distinct
learning
point
regarding
or
management.
First,
careful
examination
is
crucial,
clinicians
should
always
consider
myelopathy
patient
whose
mobility
has
dramatically
reduced.
Second,
need
pharmacological
suppression
dyskinesias
after
surgery
prevent
ongoing
injury
promote
healing.
Third,
medical
factors,
such
as
B12
deficiency,
potential
exacerbate
effects,
corrected.
Язык: Английский
Parkinson's disease and gut microbiota metabolites: The dual impact of vitamins and functional amyloids
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease,
Год журнала:
2025,
Номер
1871(6), С. 167862 - 167862
Опубликована: Апрель 18, 2025
Язык: Английский
The Impact of the Dietary Intake of Vitamin B12, Folic Acid, and Vitamin D3 on Homocysteine Levels and the Health-Related Quality of Life of Levodopa-Treated Patients with Parkinson’s Disease—A Pilot Study in Romania
Diagnostics,
Год журнала:
2024,
Номер
14(15), С. 1609 - 1609
Опубликована: Июль 26, 2024
Previous
studies
have
shown
that
the
levodopa
treatment
of
Parkinson's
disease
(PD)
elevates
circulating
homocysteine
levels,
which
are
associated
with
an
increased
risk
cardiovascular
and
neurological
disorders,
or
thrombosis.
The
present
trial
aimed
to
examine
whether
intake
vitamin
B12,
folic
acid,
D3
supplements
improved
level
quality
life
(QoL).
Язык: Английский
The Imbalance of Homocysteine, Vitamin B12 and Folic Acid in Parkinson Plus Syndromes: A Review beyond Parkinson Disease
Biomolecules,
Год журнала:
2024,
Номер
14(10), С. 1213 - 1213
Опубликована: Сен. 26, 2024
While
there
is
a
link
between
homocysteine
(Hcy),
B12
and
folic
acid
neurodegeneration,
especially
in
disorders
like
Parkinson’s
Alzheimer’s
diseases,
its
role
Parkinson
plus
syndromes
(PPS)
has
only
been
partially
investigated.
It
appears
that
elevated
Hcy,
along
with
an
imbalance
of
essential
vitamin
cofactors,
are
both
implicated
the
development
progression
parkinsonian
syndromes,
which
represent
different
disease
pathologies,
namely
alpha-synucleinopathies
tauopathies.
Attributing
potential
pathogenetic
hyperhomocysteinemia
would
be
crucial
terms
improving
diagnostic
prognostic
accuracy
these
also
for
providing
new
target
possible
therapeutic
intervention.
The
scope
this
review
to
focus
on
PPS,
special
emphasis
neurodegenerative
process
their
implication
approach
disorders.
Язык: Английский
Effects of Vitamins on Some Neurological Diseases
Опубликована: Июнь 10, 2024
Vitamins
are
micronutrients
from
various
food
sources
that
the
nervous
system
needs
for
proper
functioning.
Vitamin
deficiencies
or
imbalances
can
adversely
affect
neuronal
metabolism
and
lead
to
neurodegenerative
diseases.
may
have
therapeutic
properties
in
Parkinson’s
disease
thanks
their
antioxidant
anti-inflammatory
properties,
while
water-
fat-soluble
vitamins
help
prevent
amyloid
beta
tau
pathology
Alzheimer’s
disease.
Язык: Английский
Metabolomic and Lipidomic Analysis of Manganese-Associated Parkinsonism: a Case-Control Study in Brescia, Italy
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 6, 2024
Excessive
Manganese
(Mn)
exposure
is
neurotoxic
and
can
cause
Mn-Induced
Parkinsonism
(MnIP),
marked
by
cognitive
motor
dysfunction.
Although
metabolomic
lipidomic
research
in
(PD)
patients
exists,
it
remains
limited.
This
study
hypothesizes
distinct
profiles
based
on
status,
disease
diagnosis,
their
interaction.
Язык: Английский